Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 10/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053540 | 1.00 | L3MBTL1 (0.66) | L3MBTL1GAAMAPTALDH1A1APP | |
| SCHEMBL8672706 | 0.91 | L3MBTL1 (0.78) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL3046764 | 0.90 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL3044200 | 0.88 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTALDH1A1APP | |
| SCHEMBL28855980 | 0.88 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTALDH1A1APP | |
| SCHEMBL3053864 | 0.88 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTALDH1A1APP | |
| SCHEMBL834525 | 0.86 | L3MBTL1 (0.88) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL12252924 | 0.85 | L3MBTL1 (0.69) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL13894709 | 0.85 | L3MBTL1 (0.68) | L3MBTL1GAAMAPTALDH1A1LMNA | |
| SCHEMBL22495314 | 0.85 | PKM (0.66) | L3MBTL1ALDH1A1APPRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | NAGASAKI UNIVERSITY (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2030635-A1 | COMPOSITION FOR DIAGNOSING AMYLOID-RELATED DISEASE | Nagasaki University (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | APP, FABP7, APBA1 | L3MBTL1 1804/4885GAA 2094/4885MAPT 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.